Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
Authors:
- 25 January 2018
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 1 (1) , CD003869
Abstract
Background This is an update to the review published in the Cochrane Library (2012, Issue 4). It is estimated that 20% to 40% of people with cancer will develop brain metastases during the course of their illness. The burden of brain metastases impacts quality and length of survival. Objectives To assess the effectiveness and adverse effects of whole brain radiotherapy (WBRT) given alone or in combination with other therapies to adults with newly diagnosed multiple brain metastases. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase to May 2017 and the National Cancer Institute Physicians Data Query for ongoing trials. Selection criteria We included phase III randomised controlled trials (RCTs) comparing WBRT versus other treatments for adults with newly diagnosed multiple brain metastases. Data collection and analysis Two review authors independently assessed trial quality and abstracted information in accordance with Cochrane methods. Main results We added 10 RCTs to this updated review. The review now includes 54 published trials (45 fully published reports, four abstracts, and five subsets of data from previously published RCTs) involving 11,898 participants. Lower biological WBRT doses versus control The hazard ratio (HR) for overall survival (OS) with lower biological WBRT doses as compared with control (3000 cGy in 10 daily fractions) was 1.21 (95% confidence interval (CI) 1.04 to 1.40; P = 0.01; moderate‐certainty evidence) in favour of control. The HR for neurological function improvement (NFI) was 1.74 (95% CI 1.06 to 2.84; P = 0.03; moderate‐certainty evidence) in favour of control fractionation. Higher biological WBRT doses versus control The HR for OS with higher biological WBRT doses as compared with control (3000 cGy in 10 daily fractions) was 0.97 (95% CI 0.83 to 1.12; P = 0.65; moderate‐certainty evidence). The HR for NFI was 1.14 (95% CI 0.92 to 1.42; P = 0.23; moderate‐certainty evidence). WBRT and radiosensitisers The addition of radiosensitisers to WBRT did not confer additional benefit for OS (HR 1.05, 95% CI 0.99 to 1.12; P = 0.12; moderate‐certainty evidence) or for brain tumour response rates (odds ratio (OR) 0.84, 95% CI 0.63 to 1.11; P = 0.22; high‐certainty evidence). Radiosurgery and WBRT versus WBRT alone The HR for OS with use of WBRT and radiosurgery boost as compared with WBRT alone for selected participants was 0.61 (95% CI 0.27 to 1.39; P = 0.24; moderate‐certainty evidence). For overall brain control at one year, the HR was 0.39 (95% CI 0.25 to 0.60; P < 0.0001; high‐certainty evidence) favouring the WBRT and radiosurgery boost group. Radiosurgery alone versus radiosurgery and WBRT The HR for local brain control was 2.73 (95% CI 1.87 to 3.99; P < 0.00001; high‐certainty evidence)favouring the addition of WBRT to radiosurgery. The HR for distant brain control was 2.34 (95% CI 1.73 to 3.18; P < 0.00001; high‐certainty evidence) favouring WBRT and radiosurgery. The HR for OS was 1.00 (95% CI 0.80 to 1.25; P = 0.99; moderate‐certainty evidence). Two trials reported worse neurocognitive outcomes and one trial reported worse quality of life outcomes when WBRT was added to radiosurgery. We could not pool data from trials related to chemotherapy, optimal supportive care (OSC), molecular targeted agents, neurocognitive protective agents, and hippocampal sparing WBRT. However, one trial reported no differences in quality‐adjusted life‐years for selected participants with brain metastases from non‐small‐cell lung cancer randomised to OSC and WBRT versus OSC alone. Authors' conclusions None of the trials with altered higher biological WBRT dose‐fractionation schemes reported benefit for OS, NFI, or symptom control compared with standard care. However, OS and NFI were worse for lower biological WBRT dose‐fractionation schemes than for standard dose schedules. The addition of WBRT to radiosurgery improved local and distant brain control in selected people with brain metastases, but data show worse neurocognitive outcomes and no differences in OS. Selected people with multiple brain metastases from non‐small‐cell lung cancer may show no difference in OS when OSC is given and WBRT is omitted. Use of radiosensitisers, chemotherapy, or molecular targeted agents in conjunction with WBRT remains experimental. Further trials are needed to evaluate the use of neurocognitive protective agents and hippocampal sparing with WBRT. As well, future trials should examine homogeneous participants with brain metastases with focus on prognostic features and molecular markers.Keywords
This publication has 75 references indexed in Scilit:
- Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain MetastasesJournal of Clinical Oncology, 2012
- Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 StudyJournal of Clinical Oncology, 2011
- Randomized Comparison of Whole Brain Radiotherapy, 20 Gy in Four Daily Fractions Versus 40 Gy in 20 Twice-Daily Fractions, for Brain MetastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancerBritish Journal of Cancer, 2009
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- The palliation of brain metastases: Final results of the first two studies by the radiation therapy oncology groupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1980
- THE MANAGEMENT OF METASTASES TO THE BRAIN BY IRRADIATION AND CORTICOSTEROIDSAmerican Journal of Roentgenology, 1971